The U.S. specimen collection cards market is expected to experience significant growth in the coming years due to the increasing prevalence of infectious diseases and the growing demand for diagnostics testing. Technological advancements in card-based specimen collection methods are also expected to drive market growth.
Market Dynamics:
Two industry restraints for the U.S. specimen collection cards market include the stringent regulatory requirements for medical devices and the lack of awareness about the benefits of card-based specimen collection methods among healthcare professionals. These factors could hinder market growth in the coming years.
The U.S. specimen collection cards market can be segmented based on the type of specimen collected, end-user, and application. Specimen types may include blood, urine, saliva, and others. End-users may include hospitals, diagnostic laboratories, point-of-care testing facilities, and others. Applications may include infectious disease testing, genetic testing, drug testing, and others.
Competitive Landscape:
Key players in the U.S. specimen collection cards market include companies such as Becton, Dickinson and Company, Cardinal Health, Thermo Fisher Scientific, Merck KGaA, and PerkinElmer. These companies are focusing on product innovation, strategic partnerships, and mergers and acquisitions to strengthen their market presence and gain a competitive edge in the market.